Guangzhou LBP Medicine Science & Technology Co., Ltd. Stock

Equities

688393

CNE1000043R4

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. 06:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
16.26 CNY -0.25% Intraday chart for Guangzhou LBP Medicine Science & Technology Co., Ltd. -11.68% -34.88%
Sales 2021 439M 60.64M Sales 2022 507M 70.08M Capitalization 2.05B 284M
Net income 2021 79M 10.91M Net income 2022 42M 5.8M EV / Sales 2021 5.06 x
Net cash position 2021 625M 86.29M Net cash position 2022 242M 33.38M EV / Sales 2022 3.57 x
P/E ratio 2021
35.8 x
P/E ratio 2022
48.9 x
Employees -
Yield 2021
0.89%
Yield 2022
0.64%
Free-Float 43.29%
More Fundamentals * Assessed data
Dynamic Chart
LBP Medicine Gets Certificate for HER2 Antibody Reagent MT
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Certain A Shares of LBP Medicine Science & Technology Co., Ltd are subject to a Lock-Up Agreement Ending on 20-AUG-2023. CI
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Guangzhou Anbiping Medical Laboratory Co., Ltd. announced that it expects to receive CNY 20 million in funding from Guangzhou LBP Medicine Science & Technology Co., Ltd., Guangzhou Anbiping No. 1 Investment Partnership Enterprise (Limited Partnership), Guangzhou Anbiping No. 2 Investment Partnership Enterprise (Limited Partnership) CI
Guangzhou Lbp Medicine Science & Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Guangzhou LBP Medicine Science & Technology Co., Ltd.(SHSE:688393) added to Shanghai Stock Exchange Composite Index CI
More news
1 day-0.25%
1 week-11.68%
Current month-16.79%
1 month-18.98%
3 months-28.08%
6 months-32.78%
Current year-34.88%
More quotes
1 week
15.30
Extreme 15.3
18.14
1 month
15.30
Extreme 15.3
23.97
Current year
12.83
Extreme 12.83
25.85
1 year
12.83
Extreme 12.83
34.48
3 years
12.83
Extreme 12.83
41.33
5 years
12.83
Extreme 12.83
74.00
10 years
12.83
Extreme 12.83
74.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 05-07-05
Director of Finance/CFO 41 22-05-15
Chief Administrative Officer 44 07-06-30
Members of the board TitleAgeSince
Chief Executive Officer 59 05-07-05
Director/Board Member 43 17-11-19
Director/Board Member 47 05-10-31
More insiders
Date Price Change Volume
24-04-18 16.26 -0.25% 820 000
24-04-18 16.3 -0.97% 984,621
24-04-17 16.46 +6.88% 1,102,420
24-04-16 15.4 -9.31% 1,490,029
24-04-15 16.98 -5.51% 1,554,494

End-of-day quote Shanghai S.E., April 18, 2024

More quotes
Guangzhou LBP Medicine Science & Technology Co Ltd is a China-based company mainly engaged in the research, development, production and sales of in vitro diagnostic reagents and instruments. The Company’s main products are pathological diagnostic reagents and instruments, covering three major technology platforms for cytological diagnosis, molecular diagnosis and immunodiagnosis, including LBP series, IHC series, PCR series and FISH series, such as integrated slide and dyeing machine, liquid-based cell and microorganism processing, preservation reagents, automatic nucleic acid molecular hybridization instrument, automatic slide processing system and immunochromogenic reagents, etc. Its products are mainly used in pathological diagnosis of tumors. The Company operates its businesses within the domestic market and to overseas markets.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 688393 Stock